J Korean Med Sci.  2014 Apr;29(4):468-484. 10.3346/jkms.2014.29.4.468.

Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition

• Won E
• Park SC
• Han KM
• Sung SH
• Lee HY
• Paik JW
• Jeon HJ
• Lee MS
• Shim SH
• Ko YH
• Lee KJ
• Han C
• Ham BJ
• Choi J
• Hwang TY
• Oh KS
• Hahn SW
• Park YC
• Lee MS

• KMID: 1774451
• DOI: http://doi.org/10.3346/jkms.2014.29.4.468

Abstract

This paper aims to introduce, summarize, and emphasize the importance of the 'Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition'. The guideline broadly covers most aspects of the pharmacological treatment of patients in Korea diagnosed with moderate to severe major depression according to the DSM-IV TR. The guideline establishment process involved determining and answering a number of key questions, searching and selecting publications, evaluating recommendations, preparing guideline drafts, undergoing external expert reviews, and obtaining approval. A guideline adaptation process was conducted for the revised edition. The guideline strongly recommends pharmacological treatment considered appropriate to the current clinical situation in Korea, and should be considered helpful when selecting the appropriate pharmacological treatment of patients diagnosed with major depressive disorder. Therefore, the wide distribution of this guideline is recommended.

Keyword

Depression; Pharmacological Treatment; Guideline; Korea

MeSH Terms

Antidepressive Agents/*therapeutic use
Antipsychotic Agents/therapeutic use
Databases, Factual
Depression/complications/diagnosis/*drug therapy
Drug Tolerance
Evidence-Based Practice
Humans
Monoamine Oxidase Inhibitors/therapeutic use
Neurotransmitter Uptake Inhibitors/therapeutic use
Placebo Effect
Psychotic Disorders/complications/drug therapy
Republic of Korea
Severity of Illness Index
Antidepressive Agents
Antipsychotic Agents
Monoamine Oxidase Inhibitors
Neurotransmitter Uptake Inhibitors

Reference

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global burden of disease and risk factors. Washington, D.C.: World Bank;2006.

2. Lee MS, Cha JH, Chung SK, Kim KS, Kasper S. the Executive Committee for the Korean Medication Algorithm Project for Major Depressive Disorder. The development of the Korean medication algorithm for major depressive disorder. Psychiatry Investig. 2005; 2:60–69.

3. Clinical Research Center for Depression. Evidence-based Korean pharmacological treatment guideline for depression. Seoul: ML Communication;2008.

4. Park SC, Oh HS, Oh DH, Jung SA, Na KS, Lee HY, Kang RH, Choi YK, Lee MS, Park YC. Evidence-based, non-pharmacological treatment guideline for depression in Korea. J Korean Med Sci. 2014; 29:12–22.

5. Clinical Research Center for Depression. Evidence-based Korean pharmacological treatment guideline for depression, revised edition. Seoul: ML Communication;2012.

6. Park SC, Sung SH, Han KM, Won ES, Lee HY, Paik JW, Jeon HJ, Lee MS, Shim SH, Ko YH, et al. Evidence-based Korean pharmacological treatment guideline for depression, revised edition (I): initial choice of antidepressant treatment. J Korean Neuropsychiatr Assoc. 2013; 52:253–262.

7. Sung SH, Park SC, Han KM, Won ES, Lee HY, Koo JW, Paik JW, Lee KM, Jeon HJ, Lee MS, et al. Evidence-based Korean pharmacological treatment guideline for depression, revised edition (II): antidepressant efficacy compared with placebo, difference in efficacy of antidepressants, and appropriate time of efficacy judgment in antidepressant therapy. J Korean Neuropsychiatr Assoc. 2013; 52:372–385.

8. Han KM, Park SC, Won ES, Sung SH, Lee H, Koo JW, Lee K, Lee HY, Paik JW, Jeon HJ, et al. Evidence-based Korean pharmacological treatment guideline for depression, revised edition (III): dose increment, switching, combination, and augmentation strategy in antidepressant therapy. J Korean Neuropsychiatr Assoc. 2013; 52:386–401.

9. Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. AMIA Annu Symp Proc. 2006; 359–363.

10. Kim SY KN, Shin SS, Kim DW, Ji SM, Lee SJ. ADAPTE: manual for guildeline adaptation version 1.0. Seoul: National Clinical Research Coordination Center;2009.

11. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ;. GRADE Working Group. Going from evidence to recommendations. BMJ. 2008; 336:1049–1051.

12. National Institute for Health and Clinical Excellence (NICE). Depression: the treatment and management of depression in adults (updated edition). Leicester: British Psychological Society;2010.

13. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, Matthews K, McAllister-Williams RH, Peveler RC, Scott J, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008; 22:343–396.

14. The New Zealand guidelines group. Identification of common mental disorders and management of depression in primary care. New Zealand: Ministry of Health;2008.

15. Malhi GS, Adams D, Porter R, Wignall A, Lampe L, O'Connor N, Paton M, Newton LA, Walter G, Taylor A, et al. Clinical practice recommendations for depression. Acta Psychiatr Scand Suppl. 2009; (439):8–26.

16. Practice guideline for the treatment of patients with major depressive disorder (revision): American Psychiatric Association. Am J Psychiatry. 2000; 157:1–45.

17. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: III. pharmacotherapy. J Affect Disord. 2009; 117:S26–S43.

18. Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol. 2001; 16:169–178.

19. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997; 12:99–108.

20. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000; 58:19–36.

21. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ;. WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007; 8:67–104.

22. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, Wagner EH. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996; 275:1897–1902.

23. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:85–102.

24. Professional Development & Quality Assurance prepared by a group of family physicians. Guideline on Management of Depression in Primary Care. Hong Kong: 2005.

25. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008; 149:725–733.

26. Texas Department of Mental Health and Mental Retardation (TDMHMR) in collaboration with Texas universities. Texas medication algorithm project procedural manual - major depressive disorder algorithms. Texas Department of State Health Services;2008.

27. Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology. Korean medication algorithm project for depressive disorder. Korean Neuropsychiatr Assoc;2008.

28. Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S, Lane RM. International Collaborative Group on Sertraline in the Treatment of Outpatients with Seasonal Affective Disorders. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl). 2004; 171:390–397.

29. Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR, Watson GD, Morehouse RL, Tam W, Joffe RT. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry. 1995; 152:1765–1770.

30. Ruhrmann S, Kasper S, Hawellek B, Martinez B, Höflich G, Nickelsen T, Möller HJ. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med. 1998; 28:923–933.

31. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry. 2002; 159:1869–1875.

32. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003; 64:208–214.

33. Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006; 67:1354–1361.

34. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol. 2001; 4:113–118.

35. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry. 2000; 176:421–428.

36. Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol. 2001; 4:337–345.

37. Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, Foster VJ, Metz A, Rockett CB, Wightman DS. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry. 2005; 58:658–667.

38. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7:106–113.

39. Pitts WM, Fann WE, Halaris AE, Dressler DM, Sajadi C, Snyder S, Ilaria RL. Bupropion in depression: a tri-center placebo-controlled study. J Clin Psychiatry. 1983; 44:95–100.

40. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry. 2001; 178:129–144.

41. Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2003; (2):CD004186.

42. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995; 15:16S–23S.

43. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2005; (4):CD004185.

44. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003; 326:1014.

45. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev. 2009; (3):CD007954.

46. Panzer MJ. Are SSRIs really more effective for anxious depression? Ann Clin Psychiatry. 2005; 17:23–29.

47. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev. 2000; (2):CD001851.

48. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, Geddes JR, Hardy R, Lewis G, Mason JM. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev. 2000; (4):CD002791.

49. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006; 31:122–131.

50. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008; 149:734–750.

51. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2009; 259:172–185.

52. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008; 42:22–34.

53. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007; 27:672–676.

54. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002; 180:396–404.

55. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr. Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002; 10:541–550.

56. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000; 61:656–663.

57. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008; 63:699–704.

58. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008; 69:1287–1292.

59. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, et al. Which antidepressants have demonstrated superior efficacy? a review of the evidence. Int Clin Psychopharmacol. 2007; 22:323–329.

60. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry. 1999; 174:297–303.

61. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999; 56:171–181.

62. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? a systematic review. Eur Arch Psychiatry Clin Neurosci. 2005; 255:387–400.

63. Amsterdam JD, Berwish NJ. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry. 1989; 22:21–25.

64. Gagiano CA, Müller FG, Berk M, Joubert PM, Brown RG, Schall R. Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three times daily dosage schedules. J Clin Psychopharmacol. 1995; 15:4S–9S.

65. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002; 63:331–336.

66. Bech P, Tanghøj P, Andersen HF, Overø K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl). 2002; 163:20–25.

67. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry. 1990; 51:8–11.

68. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998; 59:116–122.

69. Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol. 1991; 11:233–236.

70. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354:1231–1242.

71. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006; 67:1836–1855.

72. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004; 55:296–300.

73. Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry. 1983; 44:20–24.

74. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002; 51:183–188.

75. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR^*D report. Am J Psychiatry. 2006; 163:1531–1541.

76. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004; 65:337–340.

77. Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? a literature review of antidepressant combination therapy. J Affect Disord. 2005; 89:1–11.

78. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord. 1996; 41:201–210.

79. Nelson JC. Overcoming treatment resistance in depression. J Clin Psychiatry. 1998; 59:13–19.

80. Nemeroff CB. Augmentation strategies in patients with refractory depression. Depress Anxiety. 1996; 4:169–181.

81. Shelton RC. Treatment options for refractory depression. J Clin Psychiatry. 1999; 60:57–61.

82. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003; 64:403–407.

83. Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol. 2007; 22:179–182.

84. Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007; 19:153–159.

85. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003; 64:1057–1064.

86. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005; 330:385.

87. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord. 2005; 88:241–254.